Volume : 12, Issue : 01, January – 2025
Title:
A REVIEW ON OVERVIEW OF PHARMACOVIGILANCE
Authors :
Vanshree G. Rathod*, Vaibhav P. Gote, Swati P. Deshmukh
Abstract :
Pharmacovigilance is a critical component of public health and patient safety, encompassing the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) and other drug-related problems. With the global expansion of pharmaceutical markets and the increasing complexity of medical therapies, the need for robust pharmacovigilance systems has never been more pressing. This review highlights the evolution of pharmacovigilance, its regulatory frameworks, methodologies for data collection and analysis, and emerging challenges in the field. The integration of advanced technologies such as artificial intelligence, real-world evidence, and big data analytics is reshaping the landscape of pharmacovigilance, offering new opportunities for proactive risk management.Additionally, the role of patient-centric approaches and international collaboration in enhancing the effectiveness of pharmacovigilance systems is emphasized. The article concludes by identifying key gaps and future directions to strengthen global pharmacovigilance practices, aiming to ensure the safe and effective use of medicines worldwide.
Keywords: PV,ADR,WHO,FDA,CDSCO.
Cite This Article:
Please cite this article in press Vanshree G. Rathod et al., A Review On Overview Of Pharmacovigilance.,Indo Am. J. P. Sci, 2025; 12 (01).
Number of Downloads : 10
References:
2. Pirmohamed, M., James, S. P., Meakin, S., et al. (2004). Adverse drug reactions as a cause of admission to hospital: A retrospective analysis of 18,820 patients. BMJ, 329(7456), 15-19.
3. Sultana, J., Cutroneo, P. M., & Trifirò, G. (2013). Clinical and economic impact of adverse drug reactions. Drug Safety, 36(11), 1017-1029.
4. World Health Organization (WHO). (2020). Pharmacovigilance. WHO. Retrieved from
5. Bate, A., Evans, S. J. W., & Jick, H. (2018). Pharmacovigilance: A Global Perspective. British Journal of Clinical Pharmacology, 84(2), 214-222.
6. Lund, L. K., Søndergard, L., & Mørch, M. (2020). The Role of Pharmacovigilance in Improving Patient Safety. European Journal of Clinical Pharmacology, 76(8), 1051-1059.
7. Pirmohamed, M. (2013). Pharmacogenetics and Pharmacovigilance: The Future of Drug Safety. European Journal of Clinical Pharmacology, 69(10), 1925-1931.
8. Bourgeois, F. T. (2021). The evolving role of pharmacovigilance in patient safety. New England Journal of Medicine, 385(10), 961-963.
9. García Rodríguez, L. A., & Ruigómez, A. (2021). Pharmacovigilance and drug safety in the real-world setting. International Journal of Clinical Pharmacology and Therapeutics, 59(4), 165-172.
10. Meyer, H. J., Klemens, R., & Ziegler, D. (2019). Pharmacovigilance and the importance of real-world data. Journal of Clinical Pharmacology, 59(1), 75-82.
11. Sarganas, G., et al. (2020). Adverse drug reactions and pharmacovigilance: A comprehensive review. European Journal of Clinical Pharmacology, 76(4), 615-629.
12. Bourgeois, F. T., & Olsen, L. (2021). Pharmacovigilance and adverse drug reactions: Ensuring drug safety in real-world settings. New England Journal of Medicine, 384(17), 1633-1644.
13. García Rodríguez, L. A., & Ruigómez, A. (2021). Adverse drug reactions and the importance of pharmacovigilance systems. International Journal of Clinical Pharmacology and Therapeutics, 59(3), 197-206.
14. Meyer, H. J., Klemens, R., & Ziegler, D. (2019). Pharmacovigilance and ADR detection: Advancing safety in the healthcare system. Journal of Clinical Pharmacology, 59(1), 80-85.
15. Sarganas, G., et al. (2020). Pharmacovigilance and the identification of adverse drug reactions: A systematic review. European Journal of Clinical Pharmacology, 76(5), 741-758.
16. Vargesson, N. (2019). Rofecoxib and the lessons of its withdrawal: Impact of pharmacovigilance on drug safety. Drug Safety, 42(8), 977-986.
17. Bourgeois, F. T., & Olsen, L. (2021). Pharmacovigilance methods: Enhancing the safety of medicines. New England Journal of Medicine, 384(17), 1633-1644.
18. García Rodríguez, L. A., & Ruigómez, A. (2021). Methods in pharmacovigilance: Approaches to detecting and assessing drug safety. International Journal of Clinical Pharmacology and Therapeutics, 59(3), 197-206.
19. Meyer, H. J., Klemens, R., & Ziegler, D. (2019). Signal detection and data mining in pharmacovigilance: Approaches to identifying adverse drug reactions. Journal of Clinical Pharmacology, 59(1), 80-85.
20. Sarganas, G., et al. (2020). Post-marketing surveillance and the identification of adverse drug reactions. European Journal of Clinical Pharmacology, 76(5), 741-758.
21. Bourgeois, F. T., & Olsen, L. (2021). The evolving role of pharmacovigilance in patient safety. New England Journal of Medicine, 385(10), 961-963.
22. García Rodríguez, L. A., & Ruigómez, A. (2021). Pharmacovigilance and drug safety in the real-world setting. International Journal of Clinical Pharmacology and Therapeutics, 59(4), 165-172.
23. Meyer, H. J., Klemens, R., & Ziegler, D. (2019).
24. Ghosh, A., Bandyopadhyay, S., & Chatterjee, S. (2021). Pharmacovigilance in India: Progress and challenges. Indian Journal of Pharmacology, 53(5), 420-429.
25. Gurung, B., Khan, A. F., & Gupta, S. (2020). The Pharmacovigilance Programme of India: A critical review. Journal of Pharmacovigilance and Drug Safety, 1(3), 107-114.
26. Srinivasan, R., Singh, S., & Singh, P. (2021). Spontaneous reporting and the impact of the Pharmacovigilance Programme of India: A study of healthcare provider perspectives. Asian Journal of Pharmaceutical and Clinical Research, 14(8), 62-68.